Welcome to our dedicated page for Stereotaxis news (Ticker: STXS), a resource for investors and traders seeking the latest updates and insights on Stereotaxis stock.
Stereotaxis, Inc. (STXS) is a global leader in innovative robotic technologies aimed at improving the treatment of arrhythmias and endovascular procedures. The company's mission focuses on the discovery, development, and delivery of advanced robotic systems, instruments, and information solutions tailored for the interventional laboratory. By leveraging cutting-edge innovations, Stereotaxis helps physicians provide superior patient care with robotic precision and safety, streamline lab efficiency, and enhance procedural information integration.
Stereotaxis boasts over 100 issued patents that form the backbone of its platform. The core components of its systems have received regulatory clearance in various regions including the United States, European Union, Japan, Canada, and China, among others. This broad regulatory approval underscores the global trust and reliance on Stereotaxis' technology.
The company's revenue streams are diversified across systems, disposables, royalties, and subleases, with a significant portion generated from disposables, services, and accessories. Notably, the majority of its revenue is derived from the United States.
Through continuous innovation and dedication to serving the medical community, Stereotaxis remains at the forefront of robotic medical technology, making significant strides in improving procedural outcomes and operational efficiencies in healthcare settings worldwide.
For the latest updates and more information, visit Stereotaxis.
Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular interventions, will release its Q1 2023 financial results on May 9, 2023, before U.S. markets open. A conference call is scheduled for the same day at 10 a.m. EST to discuss the results and corporate updates. Investors can access the call by dialing 800-715-9871 (US) or 1-646-307-1963 (International), using pass code 8054202. A replay of the call will be available for one month after the live event. Stereotaxis aims to enhance patient care through its robotic solutions, having served over 100,000 patients across various regions. This announcement emphasizes the company's commitment to transparency and engagement with its shareholders, as it prepares to disclose vital financial information.
Stereotaxis (NYSE: STXS) announced that over 1,000 cardiac arrhythmia patients have been treated using the Genesis Robotic Magnetic Navigation (RMN) system since its introduction in late 2020. This advanced technology has been implemented at eight hospitals globally, including Banner University Medical Center and the National Institute of Cardiology in Poland. The Genesis RMN system enhances robotic precision and safety for cardiac ablation procedures, benefiting patients with complex cardiac diseases. With nearly two dozen robotic systems ordered, demand for the technology is growing. Stereotaxis continues to focus on providing innovative robotic solutions for minimally invasive interventions, having treated over 100,000 patients to date.
Stereotaxis (NYSE: STXS) has launched a new robotic electrophysiology program at Broward Health Medical Center in Fort Lauderdale, Florida, marking a significant advancement in cardiac care. The facility is the first in Florida and among the first in the U.S. to utilize the Genesis Robotic Magnetic Navigation System for treating complex heart rhythm disorders. This innovative technology aims to enhance patient safety and precision during cardiac ablation procedures, addressing the needs of millions affected by arrhythmias. The collaboration highlights Stereotaxis's commitment to advancing cardiac services and improving patient outcomes.
Stereotaxis (STXS) reported its financial results for Q4 and FY 2022, revealing a revenue decline to $7.3 million in Q4 from $8.2 million in Q4 2021. Full-year revenue dropped to $28.1 million from $35.0 million, attributed to hospital construction delays affecting system placements. The company recorded a net loss of $4.2 million in Q4 and an adjusted net loss of $7.8 million for the year. Despite these challenges, Stereotaxis aims for double-digit revenue growth in 2023, driven by a strong backlog of $14.8 million and expected regulatory approvals for new product innovations.
ST. LOUIS, Feb. 21, 2023 – Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, announced that Chairman and CEO David Fischel will speak at the Cowen 43rd Annual Health Care Conference. The presentation is scheduled for March 6, 2023, at 11:10 am ET, during a Fireside Discussion with Cowen's Managing Director, Josh Jennings. Fischel will also hold one-on-one meetings afterwards.
Fischel expressed enthusiasm about sharing Stereotaxis’ innovative technology and growth strategy with investors, highlighting its commitment to enhancing patient care and operational efficiency.
Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular interventions, plans to release its financial results for Q4 and the full year 2022 on March 3, 2023, before U.S. market opening. A conference call will occur at 10 a.m. EST to discuss these results and corporate developments. Investors can participate via the dial-in number 800-715-9871 (U.S. and Canada) or 1-646-307-1963 (International) with passcode 6529896. The webcast will also be available on Stereotaxis' investor relations site. This event is crucial for assessing the company's performance and future outlook following its successful applications in over 100,000 procedures globally.
FAQ
What is the current stock price of Stereotaxis (STXS)?
What is the market cap of Stereotaxis (STXS)?
What does Stereotaxis, Inc. specialize in?
What is the mission of Stereotaxis, Inc.?
Where has Stereotaxis' technology received regulatory clearance?
What are the main revenue streams for Stereotaxis, Inc.?
Who are the key executives at Stereotaxis, Inc.?
How does Stereotaxis' technology benefit physicians?
How many patents does Stereotaxis hold?
What geographic region generates the majority of Stereotaxis' revenue?
What types of procedures are enhanced by Stereotaxis' technology?
Where can I find more information about Stereotaxis, Inc.?
